# Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

> clinical trial · VERIFIED · 2026-08-20

Status: RECRUITING · Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Condition: Non-Small Cell Lung Cancer

- Company: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07329322

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.